CT SB00188

Brand name drug manufacturers and wholesalers registered in Connecticut must make drugs available for sale to generic drug developers at a price not exceeding the wholesale acquisition cost, effective October 1, 2022.

Generic drug developers seeking FDA approval or biological product licensing may purchase brand name drugs for testing and development purposes without restrictions that would block or delay their applications.

Generic drug developers receiving drugs at the wholesale acquisition cost must charge Connecticut consumers the same price or less for their manufactured generic versions.

Brand name manufacturers and wholesalers are shielded from liability for injuries caused by the generic developer's failure to include adequate safety warnings or design defects, provided they supplied the drug in accordance with this law.

Violations of the pricing requirement or price-charging requirement constitute unfair or deceptive trade practices enforceable under Connecticut's unfair trade practice statute.